KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Equity Ratio (2018 - 2026)

Takeda Pharmaceutical has reported Equity Ratio over the past 9 years, most recently at 0.5 for Q1 2026.

  • For Q1 2026, Equity Ratio rose 3.35% year-over-year to 0.5; the TTM value through Mar 2026 reached 0.5, up 3.35%, while the annual FY2026 figure was 0.5, 3.35% up from the prior year.
  • Equity Ratio was 0.5 for Q1 2026 at Takeda Pharmaceutical, up from 0.49 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.5 in Q1 2026 and bottomed at 0.43 in Q1 2022.
  • The 5-year median for Equity Ratio is 0.48 (2024), against an average of 0.47.
  • Year-over-year, Equity Ratio rose 7.61% in 2022 and then increased 1.11% in 2025.
  • Over 5 years, Equity Ratio stood at 0.43 in 2022, then grew by 5.52% to 0.46 in 2023, then grew by 5.75% to 0.48 in 2024, then grew by 1.11% to 0.49 in 2025, then grew by 3.35% to 0.5 in 2026.
  • The last three reported values for Equity Ratio were 0.5 (Q1 2026), 0.49 (Q1 2025), and 0.48 (Q1 2024) per Business Quant data.